MedTrace Logo

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

NCT00635492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2515

Last updated 2015-04-09

Study results available
· View outcomes & findings →

Summary

Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimens are being modified, what treatment modifications are made, and clinical and patient-reported outcomes.

Conditions

Interventions

DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day

DRUG

any human insulin or analog insulin(s) given in any regimen by subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • James Malone, MD · Eli Lilly and Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark
  • France
  • Germany
  • Greece
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00635492 on ClinicalTrials.gov